In view of recent clinical trials, which patients with SLE may benefit most from treatment with a type 1 interferon antagonist? Is the safety profile of this therapy acceptable today, in the era of the mutating SARS-CoV-2 pandemic?
What abnormalities in laboratory test results of a patient with newly diagnosed SLE should be most alarming?
If you were to name the 3 most important recent advances in rheumatology that are relevant for everyday practice, what would they be?
Dr Bhaskar Dasgupta from Southend University Hospital, UK, explains how to differentiate between myositis and noninflammatory myopathy and when to perform MRI and biopsy.
Dr Kim Legault from McMaster University presents the 3 most important recent advances in the management of SLE.
Dr Robert B. M. Landewé from the Amsterdam University Medical Center, The Netherlands, shares his views on the 3 most important recent advances in the management of spondyloarthritis.
Dr Daniel Aletaha shares his views on the 3 most important recent advances in the management of rheumatoid arthritis.
Dr Bhaskar Dasgupta from Southend University Hospital, UK, shares his views on the 3 most important recent advances in the management of systemic lupus erythematosus.
Is age a contraindication to the use of biologic drugs in patients with autoimmune diseases?
What do we know about the risk of cancer associated with biologic therapy?
English
Polski
Español
українська